# Reproducible chemostat cultures to eliminate eukaryotic viruses from fecal transplant material

Signe Adamberg[1], Torben Sølbeck Rasmussen[2], Sabina Brigitte Larsen[2], Xiaotian Mao[1], Dennis Sandris Nielsen[2], Kaarel Adamberg[1,3]

[1]Department of Chemistry and Biotechnology, Tallinn University of Technology, Akadeemia tee 15, Tallinn, Estonia

[2]Section of Microbiology and Fermentation, Department of Food Science, University of Copenhagen

[3]Center of Food and Fermentation Technologies, Mäealuse 2/4, 12618, Tallinn, Estonia

## ABSTRACT

The effect of fecal microbiota transplantation (FMT) on various gut-related diseases is intensively investigated in clinical trials. In addition to bacteria, the gut microbiome also contains eukaryotic, archaeal, and bacterial viruses (bacteriophages, in short phages), which collectively is referred to as the gut virome. Application of FMT in clinical settings is associated with a potential risk for the recipient of transferring infectious eukaryotic viruses or bacteria, despite strict screening procedures for the donor material. A safer and more targeted method to modulate the gut microbiota is therefore needed to extend the application width of FMT. Emerging evidence suggests that gut phages play a key role in maintaining a balanced gut microbiome as well as in FMT efficacy. Thus, a phageome from a cultured fecal donor microbiome may be a more efficient alternative to modulate the gut bacteriome than FMT. Here, we analyzed the dynamic changes of the viromes of mice cecal and human fecal matter inoculated chemostat cultures. Sequencing results showed that the relative abundance of eukaryotic viruses remarkably decreased during continuous cultivation, likely due to the lack of eukaryotic hosts. The corresponding phageome profiles showed dilution rate dependency, a reproducibility between biological replicates, and maintained high diversity of phages although being different from the inoculum phageome. This proof-of-concept study may constitute the first step of developing therapeutic tools to target a broad spectrum of gut-related diseases and thereby replacing FMT with a safer phage-mediated therapy.

## INTRODUCTION

Transplantation of fecal microbiota (FMT) has been successfully applied to treat recurrent *Clostridioides difficile* infections (rCDI) possibly through bacteriophage-mediated (bacterial viruses, in short phages) modulation of the GM landscape [1–4]. The fecal donor material used for FMT is screened for pathogenic bacteria and viruses prior FMT to ensure the safety. However, this process is

laborious and may only end up with 3% of the donor candidates passing all safety steps [5], and

screening procedures fail, there is risk of transferring disease-causing agents as emphasised by a an

incident June 2019 where two patients in the US had severe infections following FMT, of which one

patient died [6]. As an alternative to FMT, fecal virome transplantation (FVT, sterile filtrated donor

feces) has also shown promising efficacy against CDI and rCDI [2, 7, 8]. An important advantage of FVT

over FMT is the elimination of bacterial transfer as a potential threat. However, there is still the risk

of transferring disease-causing eukaryotic viruses despite the screening of donor material for known

pathogenic viruses as long-term effects of most of the viruses inhabiting the human gastrointestinal

tract are not yet studied [9, 10].

The interactions between gut bacteria and phages are complex and mutual, hence making the gut

virome an important component in health and disease [11, 12]. Microbiome abundances and diversity

are predictive of virome richness and diversity [13]. The estimated number of virus-like particles (VLP)

remains between $10^9$ and $10^{10}$ VLP per gram of feces [14–17]. The human gut virome is dominated by

phages (over 97%) while only about one tenth of those have been annotated until now [18]. The

healthy adult gut virome is highly personal and stable over time within each individual [14, 19, 20].

Phages belonging to the order *Caudovirales* are together with single stranded DNA phages (ssDNA) of

the order *Petitvirales* dominant in the human gut [10–12, 21, 22]. There are several indications that

viromes of the dysbiotic and healthy gut microbiota differ [23–25], however the causal links between

gut virome dysbiosis and disease is still poorly understood. However, the impact of the phageome on

the composition and function of the gut microbiota has been suggested to have important

consequences for health and outcome of FMT or FVT treatments [2, 26–29].

While phages only infect bacterial and not eukaryotic cells, we aimed to develop methodology to

produce active enteric phage communities with minimized amounts of eukaryotic viruses using two

different inocula; murine cecal and human fecal microbiota. Of which the chemostat propagated

murine gut virome ability to improve gut microbiota balance was evaluated in preclinical studies

representing animal models with distinct disease etiologies, CDI [8] and diet-induced obesity [30]. Our

recent studies highlighted the importance of dilution rate on the composition of cultured fecal

microbiota [31, 32]. The cultivation conditions and substrates were chosen to sustain the highest

microbial diversity based on previous knowledge. Dynamics of the chemostat cultures was followed

by determination of bacterial and viral composition, growth characteristics and metabolic products.

We hypothesized that eukaryotic viruses would be washed out in chemostat culture due to the

dilution effect. To our knowledge, the dynamic changes of enteric phages in chemostat cultures have

not been described earlier.

## METHODS

**Chemostat inocula**

Chemostat cultivations were carried out with two different intestinal inocula of mouse and human origin, respectively. Cecal contents of mice from different vendors were pooled, as previously we have shown that mice from different vendors represents distinctly different gut microbiota profiles (both the bacterial and viral community) [33, 34]. In total 18 C57BL/6N male mice were purchased to harvest intestinal content for downstream applications. The mice were five weeks old at arrival and purchased from three vendors, represented by 6 C57BL/6NTac mice (Taconic, Lille Skensved, Denmark), 6 C57BL/6NRj mice (Janvier, Le Genest-Saint Isle, France), and 6 C57BL/6NCrl mice (Charles River, Sulzfeld, Germany) and ear marked at arrival. Animal housing was carried out at Section of Experimental Animal Models, University of Copenhagen, Denmark, under the conditions as described previously [33]. For 13 weeks the mice were fed *ad libitum* low-fat diet (LF, Research Diets D12450J, USA) until termination at 18 weeks old and their body weight were measured every second week. To preserve the viability of the strict anaerobic bacteria, 6 mice from each vendor (in total 18 mice) were sacrificed by cervical dislocation and immediately transferred to a jar containing an anaerobic sachet (cat. no. AN0035A AnaeroGen, Thermo Fisher Scientific) and subsequently to an anaerobic chamber (containing ~93 % $N_2$, ~2 % $H_2$, ~5 % $CO_2$) at room temperature (Model AALC, Coy Laboratory Products, Grass Lake, Michigan, USA) where cecum content of the mice was sampled. Inside the anaerobic chamber, the samples were processed according to vendor (Janvier, Charles River and Taconic); weighted, suspended in an anoxic 1:1 mixture of PBS (NaCl 137 mM, KCl 2.7 mM, Na2HPO4 10 mM, KH2PO4 1.8 mM) and 50% glycerol and homogenized in BagPage® 100 mL filter bags (Interscience, Saint-Nom-la-Bretèche, France) with a laboratory stomacher (Stomacher 80, Seward, UK) at medium speed for 120 seconds. The cecum content from mice from all vendors were mixed, and the pooled cecum content was divided into 6 cryotubes ~ 0.5 g cecum content in each, one for each chemostat run. The samples were frozen and kept at -80°C until use in chemostat experiments. The abovementioned processes are illustrated with a flow-diagram (Supplementary Fig. S1). All procedures regarding the handling of these animals used for donor materiel were carried out in accordance with the Directive 2010/63/EU and the Danish Animal Experimentation Act with the license ID: 2012-15-2934-00256.

The human study was approved by Tallinn Medical Research Ethics Committee, Estonia (protocol no. 554). Fecal samples from seven healthy donors (age 19-37 years, Caucasian, three male and four

female) were diluted five times in dimethyl sulfoxide phosphate saline buffer, pooled in equal volumes

and stored frozen at -80°C until use as described previously in Adamberg et al. [35].

**Growth medium**

The base medium was prepared in 0.05 M potassium phosphate buffer containing amino acids,

mineral salts and vitamins as described previously [32]. Hemin (5 mg/L), menadione (0.5 mg/L), bile

salts (0.5 g/L), $NaHCO_3$ (2.0 g/L), Tween-80 (0.5 g/L), Na-thioglycolate (0.5 g/L) and Cys-HCl (0.5 g/L,

freshly made in oxygen reduced water) were added to the base medium. Carbohydrate sources and

other components added to the medium for murine cultures were apple pectin (2 g/L, Sigma-Aldrich,

USA), chicory inulin HP (1 g/L, Orafti, Belgium), corn core xylan (2 g/L, TCI, Japan), corn starch (5 g/L,

Sigma-Aldrich, USA), larch wood arabinogalactan (2 g/L, TCI, Japan) and porcine mucin (4 g/L, Type II,

Sigma Aldrich, USA), acetic acid (0.3 g/L, Sigma-Aldrich, USA), tryptone (3 g/L, LABM, UK) and yeast

extract (3 g/L, LABM, UK) as described by Macfarlane et al. [36]. Carbohydrate sources for the human

fecal matter inoculated cultures were apple pectin (2.5 g/L, Sigma-Aldrich, USA) and porcine mucin

(2.5 g/L, Type II, Sigma Aldrich, USA). The carbohydrate sources were sterilized separately and added

to the medium before experiments. The medium for mouse cecal matter inoculated cultures

contained about three times more carbohydrates than that for human fecal matter inoculated

cultures.

**Cultivation system and culture conditions**

The cultivation system described earlier [32] was used for human fecal and mouse cecal matter

inoculated cultures. Briefly, the Biobundle cultivation system consisting of fermenter, the ADI 1030

bio-controller and cultivation control program "BioXpert" (Applikon, The Netherlands) was used. The

fermenter was equipped with sensors for pH, $pO_2$, and temperature control. Variable speed pumps

for feeding and outflow were controlled by a chemostat algorithm: D = F/V, where D is the dilution

rate (1/h), F is the feeding rate (L/h), and V is the fermenter working volume (L). pH was controlled by

adding 1M NaOH according to the pH setpoint. The medium in the feeding bottle and the culture were

flushed with sterile-filtered nitrogen gas (99.9%, AS Linde Gas, Estonia) before inoculation and

throughout the cultivation to maintain anaerobiosis. The culture volume was kept constant (600 ml

for mouse cecal and 300 ml for human fecal matter inoculated cultures). The temperature was kept

at 36.6 °C. pH was kept constant at pH=6.4 for mouse cecal and 7.0 for human fecal matter inoculated

cultures depending on the physiological pH of the host. The scheme of experiments with mouse cecal

matter inoculated culture is depicted in the Fig. 1. Three ml of the pooled mouse cecum matter were

inoculated into 600 ml medium to start the experiments. The chemostat algorithm was started 15-20

hours after inoculation, which corresponds to the middle of the exponential growth phase of the fecal culture. Three replicates were carried out with human fecal and mouse cecal inocula at two dilution rates, 0.05 1/h ($D_{low}$) and 0.2 1/h ($D_{high}$), except for experiments with mouse cecal inocula at $D_{high}$ where two experiments were performed. The stabilization of five residence times was used in all experiments. On-line and at-line parameters used for experiment control are depicted on the Supplementary Fig. S2.

**Analytical methods**

Samples from the outflow were collected on ice, centrifuged (14,000 g, 5 min, 4 °C) and stored separately as pellets (at -80°C) and supernatants (at -20°C) until further analyses. For chromatographic analyses, culture supernatants were filtered using AmiconR Ultra-10K Centrifugal Filter Devices, cut-off 3 kDa according to the manufacturer's instructions (Millipore, USA). The concentrations of organic acids (succinate, lactate, formate, acetate, propionate, isobutyrate, butyrate, isovalerate and valerate) and ethanol were determined by high-performance liquid chromatography (HPLC, Alliance 2795 system, Waters, Milford, MA, USA), using BioRad HPX-87H column (Hercules, CA, USA) with isocratic elution of 0.005 M H2SO4 at a flow rate of 0.5 mL/min and at 35 °C. Refractive index (RI) (model 2414; Waters, USA) and UV (210 nm; model 2487; Waters, USA) detectors. Analytical grade standards were used for quantification of the substances. The detection limit for the method was 0.1 mM.

The composition of the gas outflow ($H_2$, $CO_2$, $H_2S$, $CH_4$, and $N_2$) was analyzed using an Agilent 490 Micro GC Biogas Analyzer (Agilent 269 Technologies Ltd., USA) connected to a thermal conductivity detector. The volume of the gas flow was regularly recorded using MilliGascounter (RITTER Apparatebau GMBH & Co, Germany).

The Redox potential of the growth medium and culture supernatant was measured by a pH/Redox meter using an InLab®Redox electrode (Mettler Toledo, USA). The biomass dry weight was measured gravimetrically from 10 ml culture by centrifugation (6,000 rpm, 20 min), washing the biomass with distilled water and drying in an oven at 105°C for 20 h.

**Pre-processing of samples for separation of viruses and bacteria**

Culture and inoculum samples were included to investigate microbiome changes over time. Separation of the viruses and bacteria from the culture/inoculum samples generated a pellet and supernatant by centrifugation and 0.45 µm filtering as described previously [33]. The volume of culture/inoculum homogenate was adjusted to 5 mL using SM buffer.

**Bacterial DNA extraction, sequencing and pre-processing of raw data**

Human gut bacteriome data have been previously published [32] but to minimize errors due to using different data processing methods, human gut bacteriome sequences were reanalyzed using the same pipeline as described above for analysis of mice samples. Bead-Beat Micro AX Gravity (mod.1) kit from A&A Biotechnology (Gdynia, Poland) was used to extract bacterial DNA from the culture/fecal pellet by following the instructions of the manufacturer. The final purified DNA was stored at -80ºC and the DNA concentration was determined using Qubit HS Assay Kit (Invitrogen, Carlsbad, California, USA) on the Qubit 4 Fluorometric Quantification device (Invitrogen, Carlsbad, California, USA). The bacterial community composition was determined by NextSeq-based (Illumina) high-throughput sequencing (HTS) of the 16S rRNA gene V3-region, as previously described [24]. Quality-control of reads, de-replicating, purging from chimeric reads and constructing zOTU was conducted with the UNOISE pipeline [37] and taxonomically assigned with Sintax [38]. Taxonomical assignments were obtained using the EZtaxon for 16S rRNA gene database [39]. Code describing this pipeline can be accessed in github.com/jcame/Fastq_2_zOTUtable. The average sequencing depth after quality control (Accession: PRJEB58777, available at ENA) for the fecal 16S rRNA gene amplicons was 60,719 reads (min. 11,961 reads and max. 198,197 reads).

**Viral RNA/DNA extraction, sequencing and pre-processing of raw data**

The sterile filtered culture/fecal supernatant was concentrated using centrifugal filters Centrisart with a filter cut-off at 100 kDA (Sartorius) by centrifugation centrifuged at 1,500 x g at 4ºC (dx.doi.org/10.17504/protocols.io.b2qaqdse). The viral DNA/RNA was extracted from the culture/fecal supernatants using the Viral RNA mini kit (Qiagen) as previously described [33]. Reverse transcription was executed using the SuperScript VILO Master mix by following the instructions of the manufacturer and subsequently cleaned with DNeasy blood and tissue kit (Qiagen) by only following step 3-8 of the manufacturers standard protocol. In brief, the DNA/cDNA samples were mixed with ethanol, bound to the silica filter, washed two times, and eluted with 40 µL elution buffer. Multiple displacement amplification (MDA, to include ssDNA viruses) using GenomiPhi V3 DNA amplification kit (Cytiva) and sequencing library preparation using Nextera XT kit was performed at previously described [33], and sequenced at a commercial facility using the NovaSeq platform (NovoGene). The average sequencing depth of raw reads (Accession: PRJEB58787, available at ENA) for the fecal viral metagenome was 22,701,135 reads (min. 342,022 reads and max. 203,403,294 reads. The raw reads were trimmed from adaptors and the high-quality sequences (>95% quality) using Trimmomatic v0.35 [40] with a minimum size of 50 nt were retained for further analysis. High quality reads were de-replicated and checked for the presence of PhiX control using BBMap (bbduk.sh)

(https://www.osti.gov/servlets/purl/1241166). Virus-like particle-derived DNA sequences were

subjected to within-sample de-novo assembly-only using Spades v3.13.1 [41] and the contigs with a

minimum length of 2,200 nt, were retained. Contigs generated from all samples were pooled and de-

replicated at 90% identity using BBMap (dedupe.sh). Prediction of viral contigs/genomes was carried

out using VirSorter2 [42] ("full" categories | dsDNAphage, ssDNA, RNA, Lavidaviridae, NCLDV |

viralquality ≥ 0.66), vibrant [43] (High-quality | Complete), and checkv [44] (High-quality | Complete).

Taxonomy was inferred by blasting viral ORF against viral orthologous groups (https://vogdb.org) and

the Lowest Common Ancestor (LCA) for every contig was estimated based on a minimum e-value of

$10e^{-5}$. Phage-host prediction was determined by blasting (85% identity) CRISPR spacers and tRNAs

predicted from >150,000 gut species-level genome bins (SGBs) [45, 46]. Following assembly, quality

control, and annotations, reads from all samples were mapped against the viral (high-quality) contigs

(vOTUs) using the bowtie2 [47] and a contingency-table of reads per Kbp of contig sequence per

million reads sample (RPKM) was generated, here defined as vOTU-table (viral contigs). Code

describing this pipeline can be accessed in github.com/jcame/virome_analysis-FOOD. Viral mock

communities (phage C2, T7, P35, MS2, Phi6, PhiX174, T4, and PMBT5) were used as positive controls

to evaluate if the library preparation and sequencing could detect ss/dsDNA and ss/dsRNA viruses

with a titer of ~$10^6$ PFU/mL from both pure phage culture as well as spiked fecal matrices.

**Bioinformatic analysis of bacterial and viral sequences**

Initially the dataset was purged for zOTU's/viral contigs, which were detected in less than 5% of the

samples, but the resulting dataset still maintained 99.5% of the total reads. Cumulative sum scaling

(CSS) [48] was applied for the analysis of beta-diversity to counteract that a few zOTU/viral contigs

represented a large fraction of count values, since CSS have been benchmarked with a high accuracy

for the applied metrics [49]. CSS normalization was performed using the R software using the

metagenomeSeq package [50]. R version 4.2.2 [51] was used for subsequent analysis and presentation

of data. The main packages used were phyloseq [52], vegan [53], deseseq 2 [54], ampvis2 [55], ggpubr,

and ggplot2 [56]. A-diversity analysis was based on raw read counts and statistics were based on

ANOVA. B-diversity was represented by Bray Curtis dissimilarity metrics and statistics were based on

PERMANOVA.

# RESULTS

With the aim of generating viromes depleted of eukaryotic viruses, mouse cecal and human fecal

matter were propagated initially as batch cultures and subsequently in chemostat mode at two

different dilution rates ($D_{low}$, 0.05 1/h and $D_{high}$, 0.2 1/h) for five residence times. The overall concept

for both cultures (i.e dilution rates, temperature, and pH) was the same except for some differences
in the media composition. Most importantly, the total carbohydrate concentration was three times
higher in the medium for mouse-mimicking conditions compared to that for the human conditions
mimicking cultures (15.2 g/L vs 5 g/L, respectively), to resemble the high content of complex
carbohydrate in mice chow feed.

**Wash-out of eukaryotic viruses from chemostat cultures**
The relative abundance of eukaryotic viruses decreased already after batch phase and were almost
depleted after five residence times in chemostats of both mouse cecal and human fecal matter
inoculated cultures (Fig. 2). The relative abundance of eukaryotic viruses after batch phase was
0.3±0.2 % and 0.4±0.2 % (average ± standard deviation) in mouse cecal and in human fecal matter
inoculated cultures, respectively. During the chemostats relative abundance of eukaryotic viruses
declined to 0.006 % and 0.04 % in mice cecal and human fecal matter inoculated cultures at slow
dilution rates, respectively. At the same time, the bacterial virome maintained high diversity in the
chemostat phase and the number of bacterial viral OTUs remained at least 1000 times higher than
these of eukaryotic viral OTUs (Fig. 3 and Supplementary Fig. S3).
Both eukaryotic DNA viruses and phages were identified in both inocula (Fig. 3). RNA viruses
(*Leviviridae* and *Cystoviridae*) were found only in human feces and their count in mouse cecal matter
remained below detection limit of virus particles ($10^6$ VLP/mL). The most abundant taxon of eukaryotic
viruses in mouse virome was *Mimiviridae* and the abundances of other identified viral taxa
(*Herpesviridae* and *Parvoviridae*) were two magnitudes lower than *Mimiviridae*. Similarly, *Mimiviridae*
and *Circoviridae* were the most abundant eukaryotic viruses in human feces. However, their relative
abundance from all viruses was below 1%. Of note, nearly half of the vOTUs remained unidentified in
both mouse and human inocula.

**Reproducibility of the chemostat-cultured viromes**
Chemostat experiments showed that bacterial and archaeal viruses were persistent to continuous
culturing of gut microbiota and showed the dilution rate specific patterns. The diversity of the bacterial
virome was significantly related to the dilution rate (Fig. 4). The Shannon index of viromes of mouse
cecal matter inoculated cultures remained high even at the end of low dilution rate chemostat while
remarkable reductions of diversity were observed at high dilution rate. In cultures inoculated with
fecal matter of human origin, no clear associations were seen between the virome diversity and
cultivation conditions. However, Shannon indices of bacteriomes of human fecal matter inoculated
cultures were higher in chemostats than these in batch cultures (Supplementary Fig. S4). The main

archaeal viral taxon was *Bicaudavirus* and its abundance was relatively stable in batch and chemostat
modes in both mouse cecal and human fecal matter inoculated cultures (data not shown).

When examining overall virome and bacteriome compositional patterns, Fig. 4 shows that inocula and
samples of batch, slow and fast chemostat propagation clustered into distinct groups. Viromes of
batch samples were closer to these of inoculum samples as there were no outflow but also show
persistence of eukaryotic viruses in these conditions. More importantly, our results indicate good
reproducibility of chemostat experiments as clearly separated clusters of chemostat samples were
observed. Similar distinct clustering was observed also for the bacteriome (see below and
Supplementary Fig. S4).

**The effect of dilution rate on the composition of bacteriomes and corresponding viromes**

In mouse cecal matter inoculated batch cultures more than 90% of viral taxa could be identified while
in chemostats the number of unidentified viruses increased up to 50% at both dilution rates. In the
end of the batch phase, the bacteriome of the mouse cecal matter inoculated culture was dominated
by *Bacteroides*, lactobacilli and *Enterobacteriaceae*. Correspondingly, the main taxa of viruses were
*Microviridae* and *Siphoviridae* (Fig. 3), which include many viruses related to *Escherichia* and
lactobacilli [57, 58]. *Microviridae*, the most abundant taxa in the inoculum decreased significantly
already in the batch phase and were mostly washed out for the end of fast chemostat. However, in
slow chemostat, *Microviridae* were still present in noticeable amounts by the end of experiment.
Other prevalent taxa in the virome at low dilution rate were *Myoviridae* and *Podoviridae*.

The most abundant vira in human fecal matter inoculated cultures were also *Microviridae* (more than
70%) followed by *Siphoviridae* and *Podoviridae* while the fraction of unidentified viruses remained
below 10%. In the end of batch phase the relative abundance of *Microviridae* and other annotated
phages decreased while that of unidentified viruses increased several times compared to their
proportions in the inocula. At both dilution rates of chemostat cultures, *Microviridae* were mostly
washed out and largely replaced by viruses from the family *Myoviridae*, *Podoviridae,* and *Siphoviridae*.
*Myoviridae* and *Podoviridae* were especially abundant at high dilution rate.

The assembled viral contigs were used to predict bacterial hosts using databases of CRISPR-arrays and
tRNA profiles. According to 16S rRNA gene sequence data, the dominant taxa in the mouse inoculum
were *Ruminococcaceae*, *Lachnospiraceae* and lactobacilli, which by the end of the batch phase had
changed to *Bacteroides*, *Lactobacillus*, *Escherichia* and *Enterobacter* (Fig. 5). In the chemostat cultures
with high dilution rates (D = 0.2 1/h), the abundance of these four genera remained high. The
abundance of lactobacilli decreased from 23% to 12% while that of *Bacteroides* and enterobacteria
remained the most dominant taxa (both more than 20 %) in the end of chemostat propagation. In

chemostats with low dilution rate inoculated with mouse cecal matter, *Bifidobacterium*, *Bacteroides*, *Blautia* and an unidentified *Ruminococcaceae* became dominant. At the same time lactobacilli and *Escherichia* were washed out while *Akkermansia*, *Intestinimonas* and an unidentified *Lachnospiraceae* took over their place. Based on the virome host prediction analyses, the prevalence of *Bacteroides* related viruses decreased more than five times at low dilution rate being negligible at the end of chemostat propagation (Supplementary Fig. S4). Higher bacteriome diversity was reflected also in higher virome diversity. There were viruses related to genera *Akkermansia*, *Blautia*, *Enterococcus* and *Lachnoclostridium*, but viruses related to bifidobacteria and *Ruminococcaceae* were not detected (Supplementary Fig. S4).

Completely different patterns could be seen in chemostats inoculated with fecal matter of human origin. These were dominated by *Escherichia* and *Enterococcus* in the end of batch phase. It can be explained by the remarkable differences of the composition of human fecal and mouse cecal inocula although the dominant bacterial taxa were comparable. In steady state (end of chemostat), the composition of cultured mouse and human microbiota were more similar. *Bacteroides*, enterobacteria, bifidobacteria and *Clostridium* were abundant in both cultures at high dilution rate while dominance of several *Lachnospiraceae*, *Faecalibacterium* and *Collinsella* was characteristic to human fecal matter inoculated cultures only. On the other hand, *Akkermansia* and *Ruminococcaceae* members were always characteristic of low dilution rate chemostats inoculated with either mouse cecal or human fecal matter. Virome host analysis showed that human fecal matter inoculated cultures contained mainly viruses related to *Bacteroides*, *Faecalibacterium* and *Prevotella* in the end of batch phase (Supplementary Fig. S4). The fast dilution rate promoted propagation of viruses related to *Bacteroides* but also to *Parabacteroides* and *Methanobrevibacter*. The latter was not detected in bacteriome analyses of 16S rRNA gene amplicon sequences.

**Bacterial metabolites were in accordance with the composition of microbiota**

In mouse cecal matter inoculated batch cultures, the major metabolic products were acetate and lactate, comprising about 30 and 24 mol%, respectively, followed by formate, ethanol, succinate and propionate (Fig. 6). Butyrate was almost missing, and propionate represented less than 5 % of total acids. Such metabolite pattern is in accordance with the abundance of lactobacilli, *Bacteroides,* *Enterobacteriaceae* members, and *Bifidobacterium* in mouse cecal matter inoculated batch cultures (Fig. 5).

Remarkable differences in product profiles were observed of mouse cecal matter inoculated cultures at two dilution rates, $D_{low}$ = 0.05 1/h and $D_{high}$ = 0.2 1/h (Fig. 6). The highest acetate production (61 ± 2 mol-% of total products) was at $D_{low}$, while lactic acid was not detected. Ethanol was produced in

comparable amount with butyrate and propionate (all around 10 mol-%). Production of succinate was

below 10 mol-% at $D_{low}$ and the amount of formate was marginal (0.1 mol-%) while hydrogen sulfide

was mainly detected at $D_{low}$ (1.3 ± 0.1 mmol/gDW) compared to that at $D_{high}$ (0.33 ± 0.03 mmol/gDW).

Metabolite data on the human fecal matter inoculated cultures are presented in a recent paper by

Adamberg et al [32]. When comparing the cultures of the mouse cecal and human fecal matter

inoculated cultures, the overall acid and gas production patterns were similar at high dilution rate

($D_{high}$) but differed at low dilution rate ($D_{low}$). However, propionate production was higher at $D_{low}$ and

lactate production was minor at $D_{high}$ in human fecal matter inoculated cultures [32].

# DISCUSSION

**Reproducibility of the virome propagation**

Here we aimed to produce chemostat-propagated gut viromes depleted of eukaryotic viruses. Two

different inocula (mouse cecal and human fecal matter) were grown at two different dilution rates,

$D_{low}$ = 0.05 and $D_{high}$ = 0.2 1/h. The median relative abundance of contigs of eukaryotic origin decreased

from 0.8 % and 0.6 % (mouse cecal and human fecal matter inoculated cultures, respectively) to less

than detectable amounts after five residence times in chemostat cultivation. Interestingly, the viromes

appeared to be reproducible in replicate runs as both the bacteriomes and the viromes approached

equilibrium after five residence times (Supplementary Figs. S3 and S5). It would be expected that

extended time of the chemostat process remove more eukaryotic viral particles while maintaining a

similar phageome profile. This approach provides a safe and potential effective phage-mediated gut

microbiota modulation tool to investigate or treat gut-associated diseases.

Very little is known concerning virus profiles of continuous cultures inoculated with fecal or cecal

matter. However, the composition of the virome would be expected to be reflected by the bacteriome

profile due to their inherent host-phage relationship. Interestingly, the relative abundances of phages

did not correspond to their host bacteria in the bacteriome as seen from Figs. 3 and 5. In our study

*Siphoviridae* was the dominant viral family in both mouse cecal and human fecal matter inoculated

cultures, whilst *Podoviridae* and *Myoviridae* were abundantly present in the human fecal matter

inoculated chemostat culture with high dilution rate. *Microviridae*, the most abundant viral family In

both inocula was almost washed out in chemostat cultures, excluding slow chemostats started with

mouse cecal matter inoculum. High abundance of *Microviridae* in the virome can be explained by

method used for sample preparation. Multiple displacement amplification (MDA) has a preference for

ssDNA viruses, which might inflate *Microviridae* numbers [59, 60], however, Shah et al. showed

recently that using short MDA (half an hour) the data were still quantitative as confirmed by plaque

assays of double-stranded DNA (dsDNA) *Escherichia coli* infecting viruses [10].

**Impact of dilution rate**

Dilution rate is a critical factor that determines the composition and metabolism of the chemostat propagated bacteria [36]. This is in line with the human gut transit time (a sort of "dilution rate") being highly correlated to the gut microbiota diversity and composition [61, 62]. Dilution rates 0.2 and 0.05 1/h denote the fast degradation of dietary fibers in the cecum and slow grow rate in the colon [31]. Microbial metabolism directs the cross feeding between different community members and its changes affects the overall metabolic patterns and composition of the consortium. As an example, *Akkermansia*, a mucus-associated bacterium in the colon [63] was a dominant species in both mouse cecal and human fecal matter inoculated cultures at low dilution rate (0.05 1/h). On the other side the relative abundance of butyric acid producers (species of *Lachnospiraceae*) was higher at high dilution rate (0.2 1/h) [32]. In slow growing mouse cecal matter inoculated cultures higher diversity of the bacteriome was obtained similar to what has also been reported for human fecal matter inoculated chemostats by us and Asnicar et al. [62]. Additionally, high diversity of viromes at $D_{low}$ were shown in this study. Thus, $D_{low}$ in other words appear appropriate to produce diverse microbiomes and phageomes from gut microbiota cultures. In contrast, the growth of *Enterobacteriaceae* and viruses predicted to have *Enterobacteriaceae* as host was remarkably supported by fast dilution ($D_{high}$ = 0.2 1/h) in mouse cecal matter inoculated chemostat-fermentations, probably reflecting the high maximum specific growth rate of *Enterobactericeae* [64].

**Chemostat propagation of active virome for *in vivo* trials**

We have shown that chemostat can be used to produce reproducible bacterial consortia from human fecal matter inoculated cultures [32]. In this study we confirmed this phenomenon on mouse cecal matter inoculated cultures and showed also that chemostat can be used to produce reproducible viromes. The chemostat approach showed promising results for propagation of virome with minimal content of eukaryotic viruses [8, 30]. Fecal microbiota transplantation (FMT) allows modification of the intestinal microbiota in medical practice. Although FMT has been shown safe and effective in an immunocompromised CDI cohort [65], for these patients FMT is associated with several threats due to transfer of virulent microbes and viruses [66]. To overcome these potential risks, continuous cultivation of fecal inoculum can be used to diminish the load of eukaryotic viruses by dilution. In the absence of eukaryotic hosts chemostat cultures allow the propagation of bacteria and phage communities. During continuous growth over five volumes the bacterial and viral communities reach stabilized compositions that depend on the cultivation conditions (e.g dilution rate, pH, substrates).

In conclusion, we showed that chemostat cultivation is a highly promising method to generate mouse cecal and human fecal phageomes with minimal content of eukaryotic viruses. The phage populations can be used in transplantation experiments after removing all bacteria. Using the conditions tested here, the number of eukaryotic viruses can be decreased by more than hundred times of the initial load. This proof-of-concept study may constitute the first step of developing therapeutic tools to target a broad spectrum of gut-related diseases and thereby replacing FMT with a safer phage-mediated therapy.

# References

1.  Fujimoto K, Kimura Y, Allegretti JR, Yamamoto M, Zhang Y, Katayama K, et al. Functional Restoration of Bacteriomes and Viromes by Fecal Microbiota Transplantation. *Gastroenterology* 2021; **160**: 2089–2102.

2.  Ott SJ, Waetzig GH, Rehman A, Moltzau-Anderson J, Bharti R, Grasis JA, et al. Efficacy of Sterile Fecal Filtrate Transfer for Treating Patients With Clostridium difficile Infection. *Gastroenterology* 2017; **152**: 799-811.e7.

3.  Petrof EO, Gloor GB, Vanner SJ, Weese SJ, Carter D, Daigneault MC, et al. Stool substitute transplant therapy for the eradication of Clostridium difficile infection: 'RePOOPulating' the gut. *Microbiome* 2013; **1**: 1–12.

4.  Zuo T, Wong SH, Lam K, Lui R, Cheung K, Tang W, et al. Bacteriophage transfer during faecal microbiota transplantation in Clostridium difficile infection is associated with treatment outcome. *Gut* 2018; **67**: 634–643.

5.  Kassam Z, Dubois N, Ramakrishna B, Ling K, Qazi T, Smith M, et al. Donor Screening for Fecal Microbiota Transplantation. *N Engl J Med* 2019; **381**: 2070–2072.

6.  DeFilipp Z, Bloom PP, Torres Soto M, Mansour MK, Sater MRA, Huntley MH, et al. Drug-Resistant E. coli Bacteremia Transmitted by Fecal Microbiota Transplant . *N Engl J Med* 2019; **381**: 2043–2050.

7.  Kao D, Roach B, Walter J, Lobenberg R, Wong K. EFFECT OF LYOPHILIZED STERILE FECAL FILTRATE VS LYOPHILIZED DONOR STOOL ON RECURRENT CLOSTRIDIUM DIFFICILE INFECTION (RCDI): PRELIMINARY RESULTS FROM A RANDOMIZED, DOUBLE-BLIND PILOT STUDY. *J Can Assoc Gastroenterol* 2019.

8.  Rasmussen TS, Forster S, Larsen SB, Von Münchow ASGL, Tranæs KD, Brunse A, et al. Development of safe and effective bacteriophage-mediated therapies against C. difficile infections – a proof-of-concept preclinical study. *bioRxiv* 2023.

9.  Lim ES, Zhou Y, Zhao G, Bauer IK, Droit L, Ndao IM, et al. Early life dynamics of the human gut

virome and bacterial microbiome in infants. *Nat Med* 2015; **21**: 1228–1234.

10.    Shah SA, Deng L, Thorsen J, Pedersen AG, Dion MB, Castro-Mejía JL, et al. Hundreds of viral

families in the healthy infant gut. *Nat Microbiol* 2023.

11.    Cao Z, Sugimura N, Burgermeister E, Ebert MP, Zuo T, Lan P. The gut virome: A new

microbiome component in health and disease. *eBioMedicine* 2022; **81**: 104113.

12.    Tiamani K, Luo S, Schulz S, Xue J, Costa R, Khan Mirzaei M, et al. The role of virome in the

gastrointestinal tract and beyond. *FEMS Microbiol Rev* 2022; **46**: 1–12.

13.    Corzo-martinez M, García-campos G, Montilla A, Moreno FJ. Tofu whey permeate is an

efficient source to enzymatically produce prebiotic fructooligosaccharides and novel

fructosylated # -galactosides. *J Agric Food Chem* 2016.

14.    Shkoporov AN, Clooney AG, Sutton TDS, Ryan FJ, Daly KM, Nolan JA, et al. The Human Gut

Virome Is Highly Diverse, Stable, and Individual Specific. *Cell Host Microbe* 2019; **26**: 527-

541.e5.

15.    Shkoporov AN, Hill C. Bacteriophages of the Human Gut: The "Known Unknown" of the

Microbiome. *Cell Host Microbe* 2019; **25**: 195–209.

16.    Lepage P, Colombet J, Marteau P, Sime-Ngando T, Doré J, Leclerc M. Dysbiosis in

inflammatory bowel disease: A role for bacteriophages? *Gut* 2008; **57**: 424–425.

17.    Hoyles L, McCartney AL, Neve H, Gibson GR, Sanderson JD, Heller KJ, et al. Characterization of

virus-like particles associated with the human faecal and caecal microbiota. *Res Microbiol*

2014; **165**: 803–812.

18.    Gregory AC, Zablocki O, Zayed AA, Howell A, Bolduc B, Sullivan MB. The Gut Virome Database

Reveals Age-Dependent Patterns of Virome Diversity in the Human Gut. *Cell Host Microbe*

2020; **28**: 724-740.e8.

19.    Manrique P, Bolduc B, Walk ST, Van Oost J Der, De Vos WM, Young MJ. Healthy human gut

phageome. *Proc Natl Acad Sci U S A* 2016; **113**: 10400–10405.

20.    Minot S, Sinha R, Chen J, Li H, Keilbaugh SA, Wu GD, et al. The human gut virome: Inter-

individual variation and dynamic response to diet. *Genome Res* 2011; **21**: 1616–1625.

21.    Spencer L, Olawuni B, Singh P. Gut Virome: Role and Distribution in Health and

Gastrointestinal Diseases. *Front Cell Infect Microbiol* 2022; **12**: 1–11.

22.    Broecker F, Russo G, Klumpp J, Moelling K. Stable core virome despite variable microbiome

after fecal transfer. *Gut Microbes* 2017; **8**: 214–220.

23.    Norman JM, Handley SA, Baldridge MT, Droit L, Liu CY, Keller BC, et al. Disease-specific

alterations in the enteric virome in inflammatory bowel disease. *Cell* 2015; **160**: 447–460.

24.    Tao Z. Unveiling the gut virome in human health and diseases. *Int J Clin Virol* 2018; **2**: 001–

003.

25.  Clooney AG, Sutton TDS, Shkoporov AN, Holohan RK, Daly KM, O'Regan O, et al. Whole-
Virome Analysis Sheds Light on Viral Dark Matter in Inflammatory Bowel Disease. *Cell Host*
*Microbe* 2019; **26**: 764-778.e5.

26.  Brunse A, Deng L, Pan X, Hui Y, Castro-Mejía JL, Kot W, et al. Fecal filtrate transplantation
protects against necrotizing enterocolitis. *ISME J* 2022; **16**: 686–694.

27.  Beller L, Deboutte W, Vieira-Silva S, Falony G, Tito RY, Rymenans L, et al. The virota and its
transkingdom interactions in the healthy infant gut. *Proc Natl Acad Sci U S A* 2022; **119**.

28.  Rasmussen TS, Mentzel CMJ, Kot W, Castro-Mejía JL, Zuffa S, Swann JR, et al. Faecal virome
transplantation decreases symptoms of type 2 diabetes and obesity in a murine model. *Gut*
2020; **69**: 2122–2130.

29.  Rasmussen TS, Koefoed AK, Jakobsen RR, Deng L, Castro-Mejia JL, Brunse A, et al.
Bacteriophage-mediated manipulation of the gut microbiome-promises and presents
limitations. *FEMS Microbiol Rev* 2020; **44**: 507–521.

30.  Mao X, Larsen SB, Zachariassen LSF, Brunse A, Adamberg S, Castro Mejia JL, et al. A
reproducible enteric phage community improves blood glucose regulation in an obesity
mouse model. *bioRxiv* 2023.

31.  Adamberg K, Adamberg S. Selection of fast and slow growing bacteria from fecal microbiota
using continuous culture with changing dilution rate. *Microb Ecol Health Dis* 2018; **29**:
1549922.

32.  Adamberg K, Raba G, Adamberg S. Use of Changestat for Growth Rate Studies of Gut
Microbiota. *Front Bioeng Biotechnol* 2020; **8**: 1–12.

33.  Rasmussen TS, de Vries L, Kot W, Hansen LH, Castro-Mejía JL, Vogensen FK, et al. Mouse
vendor influence on the bacterial and viral gut composition exceeds the effect of diet. *Viruses*
2019; **11**.

34.  Rasmussen TS, Jakobsen RR, Castro-Mejía JL, Kot W, Thomsen AR, Vogensen FK, et al. Inter-
vendor variance of enteric eukaryotic DNA viruses in specific pathogen free C57BL/6N mice.
*Res Vet Sci* 2021; **136**: 1–5.

35.  Adamberg K, Tomson K, Talve T, Pudova K, Puurand M, Visnapuu T, et al. Levan enhances
associated growth of Bacteroides, Escherichia, Streptococcus and Faecalibacterium in fecal
microbiota. *PLoS One* 2015.

36.  Macfarlane GT, Macfarlane S, Gibson GR. Validation of a Three-Stage Compound Continuous
Culture System for Investigating the Effect of Retention Time on the Ecology and Metabolism
of Bacteria in the Human Colon. *Microb Ecol* 1998; **44**: 180–187.

37.   Edgar RC. Updating the 97% identity threshold for 16S ribosomal RNA OTUs. *Bioinformatics*
2018; **34**: 2371–2375.

38.   Edgar R. SINTAX: a simple non-Bayesian taxonomy classifier for 16S and ITS sequences.
*bioRxiv* 2016; 074161.

39.   Kim OS, Cho YJ, Lee K, Yoon SH, Kim M, Na H, et al. Introducing EzTaxon-e: A prokaryotic 16s
rRNA gene sequence database with phylotypes that represent uncultured species. *Int J Syst*
*Evol Microbiol* 2012; **62**: 716–721.

40.   Bolger AM, Lohse M, Usadel B. Trimmomatic: A flexible trimmer for Illumina sequence data.
*Bioinformatics* 2014; **30**: 2114–2120.

41.   Bankevich A, Nurk S, Antipov D, Gurevich AA, Dvorkin M, Kulikov AS, et al. SPAdes: A new
genome assembly algorithm and its applications to single-cell sequencing. *J Comput Biol*
2012; **19**: 455–477.

42.   Guo J, Bolduc B, Zayed AA, Varsani A, Dominguez-Huerta G, Delmont TO, et al. VirSorter2: a
multi-classifier, expert-guided approach to detect diverse DNA and RNA viruses. *Microbiome*
2021; **9**: 1–13.

43.   Kieft K, Zhou Z, Anantharaman K. VIBRANT: Automated recovery, annotation and curation of
microbial viruses, and evaluation of viral community function from genomic sequences.
*Microbiome* 2020; **8**: 1–23.

44.   Nayfach S, Camargo AP, Schulz F, Eloe-Fadrosh E, Roux S, Kyrpides NC. CheckV assesses the
quality and completeness of metagenome-assembled viral genomes. *Nat Biotechnol* 2021;
**39**: 578–585.

45.   Pasolli E, Asnicar F, Manara S, Zolfo M, Karcher N, Armanini F, et al. Extensive Unexplored
Human Microbiome Diversity Revealed by Over 150,000 Genomes from Metagenomes
Spanning Age, Geography, and Lifestyle. *Cell* 2019; **176**: 649-662.e20.

46.   Castro-Mejía JL, Khakimov B, Aru V, Lind M V., Garne E, Paulová P, et al. Gut Microbiome and
Its Cofactors Are Linked to Lipoprotein Distribution Profiles. *Microorganisms* 2022; **10**: 1–15.

47.   Langmead B, Salzberg SL. Fast gapped-read alignment with Bowtie 2. *Nat Methods* 2012; **9**:
357–359.

48.   Paulson JN, Colin Stine O, Bravo HC, Pop M. Differential abundance analysis for microbial
marker-gene surveys. *Nat Methods* 2013; **10**: 1200–1202.

49.   Weiss S, Xu ZZ, Peddada S, Amir A, Bittinger K, Gonzalez A, et al. Normalization and microbial
differential abundance strategies depend upon data characteristics. *Microbiome* 2017; **5**: 1–
18.

50.   Paulson J. metagenomeSeq: Statistical analysis for sparse high-throughput sequencing.

*BioconductorJp* 2014; 1–20.

51.   Team RC. R Core TeamR: A language and environment for statistical computing. R Foundation

for Statistical Computing, Vienna, Austria. 2018.

52.   McMurdie PJ, Holmes S. Phyloseq: An R Package for Reproducible Interactive Analysis and

Graphics of Microbiome Census Data. *PLoS One* 2013; **8**.

53.   Philip D. Computer program review VEGAN , a package of R functions for community ecology.

*J Veg Sci* 2003; **14**: 927–930.

54.   Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-

seq data with DESeq2. *Genome Biol* 2014; **15**: 1–21.

55.   Andersen KS, Kirkegaard RH, Karst SM, Albertsen M. ampvis2: An R package to analyse and

visualise 16S rRNA amplicon data. *bioRxiv* 2018; 10–11.

56.   Wickham H. Ggplot2. *Wiley Interdiscip Rev Comput Stat* 2011; **3**: 180–185.

57.   Niu YD, McAllister TA, Nash JHE, Kropinski AM, Stanford K. Four Escherichia coli O157:H7

phages: A new bacteriophage genus and taxonomic classification of T1-like phages. *PLoS One*

2014; **9**.

58.   Marcó MB, Garneau JE, Tremblay D, Quiberoni A, Moineau S. Characterization of two virulent

phages of Lactobacillus plantarum. *Appl Environ Microbiol* 2012; **78**: 8719–8734.

59.   d'Humières C, Touchon M, Dion S, Cury J, Ghozlane A, Garcia-Garcera M, et al. A simple,

reproducible and cost-effective procedure to analyse gut phageome: from phage isolation to

bioinformatic approach. *Sci Rep* 2019; **9**: 25–28.

60.   Yilmaz S, Allgaier M, Hugenholtz P. Multiple displacement amplification compromises

quantitative analysis of metagenomes. *Nat Methods* 2010; **7**: 943–944.

61.   Müller M, Hermes GDA, Canfora EE, Smidt H, Masclee AAM, Zoetendal EXG, et al. Distal

colonic transit is linked to gut microbiota diversity and microbial fermentation in humans

with slow colonic transit. *Am J Physiol - Gastrointest Liver Physiol* 2020; **318**: G361–G369.

62.   Asnicar F, Leeming ER, Dimidi E, Mazidi M, Franks PW, Al Khatib H, et al. Blue poo: Impact of

gut transit time on the gut microbiome using a novel marker. *Gut* 2021; **70**: 1665–1674.

63.   de Vos WM. Microbe profile: Akkermansia muciniphila: A conserved intestinal symbiont that

acts as the gatekeeper of our mucosa. *Microbiol (United Kingdom)* 2017; **163**: 646–648.

64.   Schaechter M, Maaloe O, Kjeldgaard N. Dependency on medium and temperature of cell size

and chemical composition …. *Microbiology* 1958.

65.   Suchman K, Luo Y, Grinspan A. Fecal Microbiota Transplant for Clostridioides Difficile

Infection Is Safe and Efficacious in an Immunocompromised Cohort. *Dig Dis Sci* 2022; **67**:

4866–4873.

66.    Shogbesan O, Poudel DR, Victor S, Jehangir A, Fadahunsi O, Shogbesan G, et al. A Systematic

Review of the Efficacy and Safety of Fecal Microbiota Transplant for Clostridium difficile

Infection in Immunocompromised Patients. *Can J Gastroenterol Hepatol* 2018; **2018**.

**Figures**

Fig. 1. The experimental setup of chemostat cultivations of mice cecal culture. At start one percent of
five times diluted cecal content was inoculated into a bioreactor followed by batch growth 23 h. The
chemostat culture was then run up to 5 residential times. Colored dots indicate the sampling points
for metabolite and microbiota (16S rRNA gene amplicon and virome sequencing) analyses. Similar
setup was used for human fecal cultures [32].

Fig. 2. Chemostat propagation of cecal/ fecal inocula leads to depletion of eukaryotic viruses shown
as the number or observed eukaryotic viral operational taxonomic units (vOTUs). Batch_Slow and
Batch_Fast designate the batch cultures prior the chemostat mode of low and fast dilution rates,
respectively.

Mouse                                                    Human

Fig. 3. Diversity of prokaryotic viruses during chemostat propagation of mouse cecal/ human fecal matter inoculated cultures. Depletion of eukaryotic viral families and enrichment of bacterial viral families from batch to stabilized chemostat cultures (A and C – mouse cecal matter inoculated cultures, B and D – human fecal matter inoculated cultures) presented as heatmaps. Color intensity indicates the relative abundance of eukaryotic (A, B) or prokaryotic (C, D) viral contigs from total eukaryotic or prokaryotic viral contigs, respectively. 'Slow' and 'Fast' indicate the dilution rates used in the chemostat ($D_{low}$ 0.05 and $D_{high}$ 0.2 1/h, respectively). Batch_Slow and Batch_Fast designate the batch cultures prior the corresponding chemostat modes of low and fast dilution rates, respectively.

Fig. 4. Chemostat propagation of fecal inocula at different dilution rates leads to viromes with

reproducible composition shown by beta diversity (A, B) and diverse viral community shown by

Shannon index (C, D). Samples from inoculum, batch and chemostat cultures of mouse cecal (A, C) and

human fecal (B, D) matter inoculated cultures are shown. 'Slow' and 'fast' in the column names

indicate the dilution rate used in the chemostat ($D_{low}$ 0.05 and $D_{high}$ 0.2 1/h, respectively). Batch_Slow

and Batch_Fast designate the batch cultures prior the corresponding chemostat modes of low and fast

dilution rates, respectively. Beta diversity and Shannon indices of bacteriomes are shown on the

Supplementary Fig. S4.

Fig. 5. Bacteriome composition of mice cecal (A) and human fecal matter inoculated cultures (B) after

batch and chemostat propagation. 'Slow' and 'fast' in the column names indicate the dilution rate

used in the chemostat ($D_{low}$ 0.05 and $D_{high}$ 0.2 1/h, respectively). Batch_Slow and Batch_Fast designate

the batch cultures prior the corresponding chemostat modes of low and fast dilution rates,

respectively.

Fig. 6. Reproducibility of metabolite dynamics of chemostat propagated mouse cecal cultures at two

dilution rates. Metabolite concentrations are shown in millimoles in relation to residence time

('Volumes' on x-scale). Low dilution rate (D = 0.05 1/h) is indicated with blue lines and high dilution

rate (D = 0.2 1/h) with brown-orange lines. R indicates the number of the replicate.